Excellergy Raises $70M to Rewrite the Allergy Playbook with Trifunctional Biologics
A new force has entered the allergy‑therapeutics arena. Excellergy has announced a bold $70 million Series A round designed to advance its lead candidates—“trifunctional” Effector Cell Response Inhibitors (ECRIs)—toward clinical proof. The molecules aim to simultaneously strip IgE from bound immune cells, neutralize free IgE, and tamp down the receptor expression that fuels allergic cascades….
